Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
natural product macrolide lactone |
| gptkbp:ATCCode |
none
|
| gptkbp:canBe |
anticancer agent
Alzheimer's disease therapy HIV latency reversal agent |
| gptkbp:CASNumber |
83314-01-6
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:discoveredIn |
gptkb:Bugula_neritina
|
| gptkbp:firstIsolatedFrom |
marine bryozoan
|
| gptkbp:hasBiologicalActivity |
protein kinase C modulator
|
| gptkbp:hasInChIKey |
QXJYJXUFJABWQK-ULQZVQASSA-N
|
| gptkbp:hasMolecularFormula |
C47H68O17
|
| gptkbp:hasSMILES |
CC1=C(C(=O)OC2C(C(C(C(C2OC1=O)O)O)O)O)C
|
| gptkbp:hasUNII |
1D1Q1V6S3A
|
| https://www.w3.org/2000/01/rdf-schema#label |
bryostatin-1
|
| gptkbp:IUPACName |
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,20R,23R,25S,27R,29R,31S,33R,35S)-1,20,23,25,27,29,31,33,35-nonahydroxy-5,8,13-trimethyl-3,7,11,12,15,17,20,23,25,27,29,31,33,35-tetradecahydro-1H-cyclopenta[a]phenanthrene-2,4,6,9,10,14,16,18,19,21,22,24,26,28,30,32,34,36-octaone
|
| gptkbp:molecularWeight |
905.0 g/mol
|
| gptkbp:producedBy |
Bugula neritina symbiotic bacteria
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL375324
4444442 5280752 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:solubility |
poorly soluble in water
soluble in DMSO |
| gptkbp:synonym |
gptkb:Bryostatin-1
gptkb:Bryostatin_1 gptkb:Bryostatin_I gptkb:NSC_339555 |
| gptkbp:toxicity |
low
|
| gptkbp:bfsParent |
gptkb:Bugula_neritina
|
| gptkbp:bfsLayer |
6
|